2022 World Conference on Lung Cancer (ePosters)-EP01.01-006. Sensitive Detection of Lung Cancer Using a Multiomic Plasma Cell-Free DNA Sequencing Assay

Pdf Summary

A study conducted by Lucence Diagnostics and Lucence Health Inc. has developed a multiomic approach to detect lung cancer using a liquid biopsy assay. The assay combines the detection of circulating tumor DNA (ctDNA), DNA methylation, and fragmentation profiles of cell-free DNA (cfDNA) to improve sensitivity and accuracy in the early detection of lung cancer. The study analyzed plasma cfDNA from 254 individuals, including 91 non-cancer/healthy individuals and 163 individuals with lung cancer, of which 37.4% were in the early-stage (stage I-III). <br /><br />The assay utilized an amplicon panel to detect ctDNA in the plasma samples and a 100-amplicon panel to profile DNA methylation. Additionally, cfDNA fragment size analysis was performed to distinguish tumor-derived cfDNA fragments from healthy cfDNA fragments. A logistic regression prediction model was developed using these multiple parameters to improve lung cancer detection. <br /><br />The study found that cfDNA methylation frequencies increased with cancer stage, and cfDNA fragment size ratios were correlated with clinical and molecular features of cancer. The detection of ctDNA and variant allele frequency (VAF) increased with cancer stage. The multiomic approach showed higher sensitivity and diagnostic yield compared to the detection of ctDNA alone. At 95% specificity, the prediction model provided an additional diagnostic sensitivity of 23.9% for overall lung cancer detection. <br /><br />The researchers concluded that their multiomic approach, incorporating plasma cfDNA concentration, cfDNA methylation, fragment size ratio, and ctDNA detection, showed sensitive and accurate detection of lung cancers. The study supports the utility of comprehensive cfDNA testing for enhanced sensitivity in the early detection of lung cancer. Further validation in larger prospective cohorts is ongoing. <br /><br />These findings were presented in abstract 2347 at the World Conference on Lung Cancer (WCLC) in 2022. The study was supported by Lucence Diagnostics Pte Ltd, and the authors are employees of Lucence Health Inc or Lucence Diagnostics Pte Ltd.

Asset Subtitle

Jing Shan Lim, United States

Meta Tag

Speaker Jing Shan Lim, United States

Topic Early Detection and Screening - Biomarkers

Keywords

Lucence Diagnostics

Lucence Health Inc.

multiomic approach

lung cancer

liquid biopsy assay

circulating tumor DNA

DNA methylation

fragmentation profiles

cell-free DNA

early detection